

Accepted Manuscript

Efficient EFGR mediated siRNA delivery to Breast Cancer Cells by Cetuximab Functionalized Pluronic[®] F127/Gelatin

Diana Rafael, Francesc Martínez, Fernanda Andrade, Joaquim Seras-Franzoso, Natalia Garcia-Aranda, Petra Gener, Joan Sayós, Diego Arango, Ibane Abasolo, Simó Schwartz Jr.

PII: S1385-8947(17)32237-4
DOI: <https://doi.org/10.1016/j.cej.2017.12.114>
Reference: CEJ 18275

To appear in: *Chemical Engineering Journal*

Please cite this article as: D. Rafael, F. Martínez, F. Andrade, J. Seras-Franzoso, N. Garcia-Aranda, P. Gener, J. Sayós, D. Arango, I. Abasolo, S. Schwartz Jr., Efficient EFGR mediated siRNA delivery to Breast Cancer Cells by Cetuximab Functionalized Pluronic[®] F127/Gelatin, *Chemical Engineering Journal* (2017), doi: <https://doi.org/10.1016/j.cej.2017.12.114>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Efficient EGFR mediated siRNA delivery to Breast Cancer Cells by Cetuximab Functionalized Pluronic® F127/Gelatin

Diana Rafael^{a,*}, Francesc Martínez^{a,*}, Fernanda Andrade^{a,b}, Joaquim Seras-Franzoso^a, Natalia Garcia-Aranda^{a,c}, Petra Gener^a, Joan Sayós^d, Diego Arango^e, Ibane Abasolo^{a,b,c}, Simó Schwartz Jr.^{a,b,#}

^aDrug Delivery and Targeting Group, CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.

^bNetworking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 08035 Barcelona, Spain.

^cFunctional Validation & Preclinical Studies (FVPR), CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.

^dImmune Regulation and Immunotherapy Group, CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.

^eBiomedical Research in Digestive Tract Tumors Group, CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.

* These authors contributed equally to the work

Corresponding Author

Simo Schwartz Jr, MD, PhD. Drug Delivery and Targeting Group, CIBBIM Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Passeig de la Vall d'Hebron, 119-129 08035 Barcelona, Spain

E-mail: simo.schwartz@vhir.org

Acknowledgments and conflict of interest declaration

This work was funded by grant PI14/02079 from Fondo de Investigaciones Sanitarias (FIS) of ISCIII, co-financed by the European Regional Development Fund (FEDER), and grant AC15/00092 (Target4Cancer project) from Euro-NanoMed II to SS and grant 337/C/2013 (PENTRI project) from Fundació Marató TV3 (Catalonia, Spain) to IA. This work was also funded, in part, by the Spanish Asociación Española Contra el Cáncer (AECC). The Spanish Ministry of Science and Innovation supported NG-A as laboratory technician (PTA2013-8431-I). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with

Download English Version:

<https://daneshyari.com/en/article/6579958>

Download Persian Version:

<https://daneshyari.com/article/6579958>

[Daneshyari.com](https://daneshyari.com)